https://scholars.lib.ntu.edu.tw/handle/123456789/541204
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chen L.-T. | en_US |
dc.contributor.author | Lin J.-T. | en_US |
dc.contributor.author | Tai J.J. | en_US |
dc.contributor.author | Chen G.-H. | en_US |
dc.contributor.author | Yeh H.-Z. | en_US |
dc.contributor.author | Yang S.-S. | en_US |
dc.contributor.author | HSIU-PO WANG | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | Sheu B.-S. | en_US |
dc.contributor.author | Jan C.-M. | en_US |
dc.contributor.author | Wang W.-M. | en_US |
dc.contributor.author | Wang T.-E. | en_US |
dc.contributor.author | Wu C.-W. | en_US |
dc.contributor.author | Chen C.-L. | en_US |
dc.contributor.author | Su I.-J. | en_US |
dc.contributor.author | Whang-Peng J. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.date.accessioned | 2021-01-15T03:47:46Z | - |
dc.date.available | 2021-01-15T03:47:46Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0027-8874 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-25144464528&doi=10.1093%2fjnci%2fdji277&partnerID=40&md5=2abfad8b009919a802c1101cdbbbff02 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/541204 | - |
dc.description.abstract | Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken. ? The Author 2005. Published by Oxford University Press. All rights reserved. | - |
dc.relation.ispartof | Journal of the National Cancer Institute | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | amoxicillin; bismuth citrate; clarithromycin; metronidazole; omeprazole; amoxicillin; antiinfective agent; antiulcer agent; bismuth citrate; metronidazole; omeprazole; organometallic compound; adult; aged; antimicrobial therapy; article; B cell lymphoma; cancer grading; cancer growth; cancer recurrence; cancer regression; cancer staging; clinical feature; clinical trial; confidence interval; early cancer; eradication therapy; female; follow up; gastroscopy; Helicobacter infection; Helicobacter pylori; histopathology; human; human tissue; long term care; lymphocytic infiltration; major clinical study; male; mucosa associated lymphoid tissue lymphoma; multicenter study; nonhuman; patient monitoring; persistent infection; priority journal; scoring system; statistical analysis; statistical significance; stomach biopsy; treatment outcome; comparative study; disease course; disease free survival; drug administration; drug effect; Helicobacter infection; Helicobacter pylori; hospitalization; microbiology; middle aged; mucosa associated lymphoid tissue lymphoma; pathology; prospective study; stomach tumor; survival; Taiwan; time; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Mucosa-Associated Lymphoid Tissue; Male; Metronidazole; Middle Aged; Multicenter Studies; Omeprazole; Organometallic Compounds; Prospective Studies; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | - |
dc.title | Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/jnci/dji277 | - |
dc.identifier.pmid | 16174856 | - |
dc.identifier.scopus | 2-s2.0-25144464528 | - |
dc.relation.pages | 1345-1353 | - |
dc.relation.journalvolume | 97 | - |
dc.relation.journalissue | 18 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-7741-9315 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。